Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Investing.com, GenomeWeb, tradingview.com and BioSpace. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 12h ago.
Quick answers
Why is "Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T pe" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- H.C. Wainwright reiterates Kyverna stock rating on durability data Investing.com · 2d ago
- Kyverna Shooting for Complete BLA Submission for Stiff Person Syndrome CAR T-Cell Therapy This Year GenomeWeb · 2d ago
- KYTX: Miv-cel delivers durable, drug-free remission and strong safety in SPS and gMG at 1 year tradingview.com · 2d ago
- Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data BioSpace · 2d ago
- Kyverna’s cell therapy shows lasting autoimmune benefit STAT · 2d ago
- Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T Endpoints News · 2d ago
- Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags Fierce Biotech · 2d ago
Topics
Related trends
Living Drugs Transformed Blood Cancer Treatment—and That’s Just the Beginning
Advanced therapies known as 'living drugs,' including CAR T and bispecifics, are fundamentally reshaping the landscape of blood cancer treatment.
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
Bristol Myers Squibb reports successful Phase 2 results for its next-generation GPRC5D-directed CAR-T therapy targeting heavily treated myeloma patients.
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Bristol Myers Squibb stock rises as its blood cancer cell therapy succeeds in a mid-stage trial.
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.
Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial
A first-of-its-kind clinical trial demonstrates that CAR T-cell therapy can put severe rheumatoid arthritis into remission.